BriaCell Therapeutics Corporation (BCTX) Cotización

BCTX, new 52 week low

BCTX: It's actually GREEN now in price!!! (Heck, maybe there IS a "God" --- of WOMEN, hopefully!!!! And NOT some clown nailed to a cross in Naples, Italy, 2K years ago!!!!)

BCTX: I sincerely HOPE that this BCTX stock --- with GREAT news for Women's BREAST Cancer concerns --- gets monster short-SQUEEZED, like below!!! Metaphorically speaking, that is.)

Slow and Steady up

BCTX: The Markets simply do NOT give-a-fluck about WOMEN's issues of any sort!!! (BCTX could have PR'd that they have outright CURED all Breast Cancers, but this stock STILL would not have soared in price!!!)

BCTX: The only worrisome thing about anything (Medical) WOMEN's STUFF, is that they rarely if ever SOAR in price. (While mere FLUFF news about anything MEN's Medical issues --- like today's @CADL baloney PR -- often SOAR in price gloriously.)

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the study
Median OS of 13.7 months in breast cancer patients with central nervous system (CNS) metastasis treated with the Bria-IMT™ regimen alone or in combination with an immune check point inhibitor (CPI)
Five BriaCell posters (four today and one on Dec 13 th ) showcase robust survival and clinical benefit data, plus key biomarker data from Phase 2 trial of Bria-IMT™ in metastatic breast cancer (MBC)
Biomarkers identify patients who benefit from treatments with the Bria-IMT™ regimen
No toxicity related discontinuations



https://feeds.issuerdirect.com/news-release.html?newsid=7743652450762128

BCTX: Much more IMPRESSIVE stats. for this BCTX news --- vs. the baloney stats. for @CADL's Prostate Cancer results, which were in truth mere STATISTICAL ARTIFACTS and, as such, significant of NOTHING!!

BCTX OUT ON NEWS

BCTX MASSIVE NEWS FOR THIS CANADIAN BIO

BCTX BLOWING UP

BCTX PUSHING TO TOP OF THE DAILY CLOUD VERY NICE

BCTX..............................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BCTX NICE CANADIAN BIO READY FOR A DOLLAR

BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

HUGE$ In BriaCell's Phase 2 clinical study, patients treated with the same Bria-IMT™ regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients (see Table 1). Notably, 4 of 13 patients recruited in 2022 remain in survival follow-up as well, including:

Patient 01-009: Overall survival (OS) of 25 months has been reported in a patient who had failed 6 prior treatments prior to the BriaCell regimen. Stable disease and lymph node shrinkage has been recorded during 13 cycles of therapy.
Patient 07-001: OS of 24 months. She had stable disease and received 8 cycles of BriaCell's therapy.
Patient 16-003: OS of 15 months and received 8 cycles of therapy with stable disease. Prior to the BriaCell regimen, she had 7 lines of therapy, which included the progression of disease while on the antibody-drug conjugate (ADC) Enhertu.
Patient 11-018: OS of 14 months. This previously-reported responder with 100% resolution of her brain metastasis has recently completed her 19th cycle of therapy.

$BCTX No serious adverse events related to Bria-IMT™, 35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™, Pivotal Phase 3 study patient enrollment completion is expected in mid-2025

BIG NEWS https://feeds.issuerdirect.com/news-release.html?newsid=7546332967366263

BCTX...........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BCTX.........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with “Eye-Bulging” Tumor

wainwright issues buy on bctx with $15 price $$$$$$$$$$$ cure 4 breast cancer? and others

Now the co has 8.5 mil for their business plan. Great for co. U got out and missed the push up as co has cure for breast cancer. Stock will rock

BCTX........................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

Gets out now millions of offering shares at .69…12,325,000 common shares. Each common share was sold at an offering price of $0.69 per share, for gross proceeds of approximately $8.5 million,

BCTX..................................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

Sorry. Wrong Board.

BriaCell Therapeutics Announces $8.5 Million Offering

aks yourself why no BP wanted to be a part of this. Plenty of time to notice?

BCTX..........................https://stockcharts.com/h-sc/ui?s=BCTX&p=W&b=5&g=0&id=p86431144783

I'm predicting an offering this week... Company needs cash. Under $1m currently

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitor
OS of 15.6 months compares favorably with 6.7-9.3 months reported for similar patients in the literature
Ongoing Phase 3 study investigating Bria-IMT™ in similar metastatic breast cancer population
No drug related discontinuations to date
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce positive overall survival data of its Phase 2 clinical study of Bria-IMT™ in combination with an immune check point inhibitor (CPI) in late stage metastatic breast cancer.
https://www.otcmarkets.com/stock/BCTX/news/story?e&id=2978177

Don’t blink

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

Good news and it goes lower again,,,lol

BCTX new 52 week low

BCTX new 52 week low

BCTX new 52 week low

BCTX under $2

BCTX new 52 week low

BCTX new 52 week low

BCTX. Under $3

$BCTX Shows “Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer”

Press Release: https://bit.ly/4aJmAoc

$BCTX #CancerTreatment #Innovation

Does anyone have information about the stock spinoff that occurred last year with this company? I have 600 shares of the spinoff security with 0 value and has remained that way since the spinoff. Thanks…

BCTX new 52 lo

BCTX new 52 lo

BCTX 10Q due March 13

BCTX new 52 week low

BCTX new 52 week low

$BCTX is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://finance.yahoo.com/news/briacell-records-responder-remarkable-improvement-120000404.html